scholarly journals Primary bilateral diffuse large B-cell lymphoma of adrenals presenting as incidental adrenal masses

2016 ◽  
Author(s):  
Cristina Alina Silaghi ◽  
Delia Dima ◽  
Carmen Georgiu ◽  
Delia Lupu ◽  
Ionela Lungu ◽  
...  
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Adrenal Masses ◽  
Large B Cell

Abstract #984425: Diffuse Large B-cell Lymphoma Presenting As Shrinking Bilateral Adrenal Masses

2021 ◽  
Vol 27 (6) ◽  
pp. S1-S2
Author(s):  
Jennifer Fuh ◽  
Kristen Gonzales ◽  
Laura Shevy ◽  
Patricia Kapsner
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Adrenal Masses ◽  
Large B Cell

scholarly journals Gastric diffuse large B-cell lymphoma with bilateral adrenal metastasis

2019 ◽  
Vol 12 (7) ◽  
pp. e229758
Author(s):  
Muhammad Hassan ◽  
Amrendra Kumar Mandal ◽  
Jasdeep Singh Sidhu ◽  
Luz Maria Cardenas
Keyword(s):  
B Cell ◽  
Adrenal Insufficiency ◽  
Adrenal Glands ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Large B Cell Lymphoma ◽  
Severe Hypotension ◽  
Adrenal Masses ◽  
Hormonal Analysis ◽  
Large B Cell

Extranodal adrenal involvement in non-Hodgkin’s lymphoma is very rare, estimated to be around less than 0.2%. Most common sites involved are stomach, intestine and testis. It is very rare for adrenal tumours to present as primary adrenal insufficiency, with an incidence of around 1.2% in patients diagnosed with adrenal masses. Diffuse large B cell lymphoma (DLBL) originating from the stomach and metastasizing to bilateral adrenal glands is an extremely uncommon occurrence with only three cases found on review of the literature. We present a case of a 62-year-old African–American man who presented with nausea, vomiting, abdominal pain and hypotension, later being diagnosed as DLBL of the gastric antrum metastasized to bilateral adrenal glands. Initial laboratory workup revealed including hormonal analysis and cosyntropin test revealed adrenal insufficiency. The patient later died during the hospitalisation after developing respiratory failure, severe hypotension refractory to vasopressors and severe metabolic acidosis.

scholarly journals Primary Adrenal Diffuse Large B-cell Lymphoma: A Mini Review

2015 ◽  
Vol 7 (3) ◽  
pp. 65-68 ◽  
Author(s):  
Rajeev Parameswaran ◽  
Dedrick Kok Hang Chan ◽  
Poon Li Mei Michelle ◽  
Shi Wang
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Surgical Excision ◽  
Large B Cell Lymphoma ◽  
Pubmed Database ◽  
Adrenal Lymphoma ◽  
Adrenal Masses ◽  
Elevated Lactate ◽  
Large B Cell

ABSTRACT Background Primary adrenal diffuse large B-cell lymphoma are aggressive high grade lymphomas affecting elderly gentlemen and mostly present with bilateral enlarged adrenal masses associated with B symptoms, adrenal insufficiency and elevated lactate dehydrogenase. When imaged with CT or ultrasound, these lesions usually appear as heterogeneous complex large masses with low density. They appear metabolically active on PET scan. Confirmatory diagnosis is established by image guided biopsy or surgical excision. Treatment is usually with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) or CHOP like regimes. Surgery has very limited role, if any in the management of this condition. The prognosis is generally poor with only about a third of patients achieving partial or complete remission following treatment. A concise review of the literature (PubMed database; 1990–2014) on the clinical management of primary adrenal lymphoma along with a case example is discussed. How to cite this article Parameswaran R, Chan DKH, Michelle PLM, Wang S. Primary Adrenal Diffuse Large B-cell Lymphoma: A Mini Review. World J Endoc Surg 2015;7(3):65-68.

Lymphome

Praxis ◽  
2016 ◽  
Vol 105 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Andreas Lohri
Keyword(s):  
B Cell ◽  
Cell Lymphoma ◽  
B Cell Lymphoma ◽  
Staging System ◽  
Maligne Lymphome ◽  
Interim Pet ◽  
Large B Cell Lymphoma ◽  
Ann Arbor ◽  
Large B Cell

Zusammenfassung. Maligne Lymphome unterteilen sich zwar in über 60 Entitäten, das grosszellige B-Zell-Lymphom, das follikuläre Lymphom, der Hodgkin und das Mantelzell-Lymphom machen aber mehr als die Hälfte aller Lymphome aus. Im revidierten Ann Arbor staging system gelten die Suffixe «A» und «B» nur noch für den Hodgkin. «E» erscheint nur noch bei Stadien I und II. Eine Knochenmarksuntersuchung wird beim Hodgkin nicht mehr verlangt, beim DLBCL (Diffuse large B cell lymphoma) nur, falls das PET keinen Knochenmark-Befall zeigt. Der PET-Untersuchung, speziell dem Interim-PET, kommt eine entscheidende Bedeutung zu. PET-gesteuerte Therapien führen zu weniger Toxizität. Gezielt wirkende Medikamente mit eindrücklicher Wirksamkeit wurden neu zugelassen. Deren Kosten sind hoch. Eine strahlen- und chemotherapiefreie Behandlung maligner Lymphome wird in Zukunft möglich sein.

Sign in / Sign up

Export Citation Format

Share Document